TCT-645 Optical coherence tomography findings in bioresorbable scaffold thrombosis  by Karanasos, Antonios et al.
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comimbalances between trials conﬁrmed non-signiﬁcant differences between stent type
and stent thrombosis rates. The trend for a higher deﬁnite stent thrombosis rate in the
BES group was by multivariate analysis less prominent (HR 2.05 [CI95% 0.75-5.60];
p¼0.16).
Conclusions: At 1-year follow-up the biodegradable polymer-coated BES has similar
stent thrombosis rates as the durable polymer-coated EES. However, incidence of
deﬁnite stent thrombosis is numerically higher in the BES group without reaching
statistical signiﬁcance. Longer follow-up is needed to determine the safety proﬁle of
biodegradable polymer-coated BES in real world clinical practice.Events at 1 years
EES BES
p-value(n¼2,530) (n¼3,412)
Deﬁnite Stent Thrombosis
All Stent Thrombosis 0.2% (5) 0.5% (17) 0.08
Early Stent Thrombosis 0.2% (4) 0.4% (13) 0.14
Late Stent Thrombosis 0.04% (1) 0.1% (4) 0.40
Deﬁnite or Probable Stent Thrombosis
All Stent Thrombosis 0.4% (10) 0.5% (18) 0.57
Early Stent Thrombosis 0.3% (8) 0.4% (13) 0.83
Late Stent Thrombosis 0.1% (2) 0.2% (5) 0.71TCT-645
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Background: Bioresorbable scaffolds (BVS) are a new treatment for coronary artery
disease with promising results in ﬁrst-in-man studies. As their use is extending in more
complex lesions and populations, several cases of BVS thrombosis have been re-
ported. We present optical coherence tomography ﬁndings from the culprit lesion of
patients with BVS thrombosis.
Methods: Up to 1/5/2014, 442 patients received BVS in our center. Among those, 14
patients that developed deﬁnite BVS thrombosis, according to the ARC criteria, were
readmitted to our cathlab. Eight of them were imaged by optical coherence tomog-
raphy (OCT) at the time of the event. OCT images were reviewed ofﬂine and the
presence of thrombus, underexpansion, neointimal hyperplasia >50%, incomplete
scaffold apposition, and scaffold discontinuity were assessed. The current status of
dual antiplatelet therapy at the time of the event was also recorded.
Results: Thrombus was visualized in 7/8 cases, underexpansion in 1/8, neointimal
hyperplasia >50% in 2/8, incomplete scaffold apposition in 4/8, and scaffold
discontinuity in 2/8 cases. In 3 cases, dual antiplatelet therapy had been discontinued
at the time of the event. A summary of the most prominent OCT ﬁndings is presented
in the Table.Case
Type/
timing Baseline OCT ﬁndings Prominent OCT ﬁndings at event
Dual
antiplatelet
therapy
1 Acute/
same day
Thrombus at proximal stent edge,
deriving from an adjacent
ﬁbroatheroma
Yes
2 Subacute/
2 days
Thrombus overlying extensive overlap
region (7.6mm)
Yes
3 Late/
40 days
Undersizing/residual
thrombus/plaque
prolapse
Incomplete scaffold apposition with
thrombus
Yes
4 Late/
4 months
Occlusive edge restenosis Yes
5 Late/
4 months
Uncovered struts at the carina of a
bifurcation treated with T-stenting
No
6 Late/
4 months
Scaffold fracture Thrombus overlying overlap region
with underexpansion/ scaffold
fracture
No
7 Late/
7 months
Incomplete scaffold apposition/
occlusive restenosis
Yes
8 Very late/
2 years
Optimal scaffold
expansion
Late scaffold discontinuity/
incomplete scaffold apposition
No
B188 JACC Vol 64/11/Suppl B j SeptemberConclusions: Discontinuation of antiplatelet therapy was identiﬁed in some patients
as a reason for BVS thrombosis, however, in the majority of the cases mechanical
factors were identiﬁed by OCT as a substrate. OCT can provide useful insights on the
pathomechanisms of this complication.
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Background: Incidence of late stent thrombosis (ST) is increasing due to the persistent
risk of thrombosis after implantation. Most of the cases are treated with percutaneous
coronary intervention (PCI). PCI of late-ST with additional stent implantation has been
associated with worse outcomes. Intravascular ultrasound (IVUS) imaging is able to
assess the pathological causes of late-ST and guide the best treatment. The objectives of
this study are to describe the IVUS ﬁndings of late-ST and compare outcomes between
patients treated without and with additional stent implantation.
Methods: All patients with late-ST (>1 month) undergoing IVUS-guided PCI were
included in 7 Spanish institutions. The operators were left to decide the PCI treatment:
balloon angioplasty (POBA) vs. stent implantation. Four IVUS ﬁndings were
assessed: late incomplete stent apposition (LISA), aneurysm, stent underexpansion
and excessive neointimal proliferation.
Results: 117 patients were included (54.4% drug-eluting stents). The median time
after implantation was 3.5 years. ST was presented as ST-elevation myocardial
infarction in 99 (84.1%) patients. Additional stent implantation was used in 54 patients
(46.2%). Prior to intervention, there were no differences in LISA (71.4% vs. 63.0%;
p¼0.33), aneurysm (11.1% vs. 11.1%; p¼1.0), underexpansion (31.7% vs. 18.5%;
p¼0.10) or excessive neointimal proliferation (11.1% vs. 22.2%; p¼0.10) between
patients treated with POBA vs. additional stent implantation. After PCI, persistent
LISA was observed in 25.4% vs. 51.9% of patients (p¼0.01), respectively. Persistent
underexpansion was observed in 6.3% and 14.8% (p¼0.05). Follow-up was obtained
at 2.0 years. Cardiac death was observed in 3.4% vs. 5.8% of patients treated without
and with additional stent (p¼0.55). Deﬁnite or probable re-thrombosis was observed
in 1.7% vs. 7.7% (p¼0.13), respectively.
Conclusions: The most frequent IVUS ﬁndings of late-ST are LISA and under-
expansion. POBA seems to improve these IVUS-ﬁndings with respect to additional
stent implantation. IVUS-guided treatment of deﬁnite ST is associated with favorable
outcomes independently of the use of additional stent implantation.
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Background: Stent thrombosis (ST) has been described as a rare event in current
drug-eluting stent (DES) era; however, its occurrence has been associated with high
morbimortality, including fatality rates up to 50%. Previous studies have shown ST
could be increased in complex subsets; however, the incidence and predictors of ST
after DES overtime are still no fully understood
Methods: A total of 5,408 pts with >8,000 coronary lesions undergoing routine or
emergency PCI were prospectively (and consecutively) enrolled in the DESIRE
(Drug-Eluting Stent In the REal World) registry at single institution between May/
2002 and May/2012 (enrollment ongoing). By protocol, clinical follow-up was per-
formed at 1 and 6 months, and yearly up to 12 years post-index procedure (97%).
Stent thrombosis (ST) was deﬁned according to the propositions of the Academic
Research Consortium.
Results:Mean age was 65 years, 32% had diabetes, and 16% had clinical presentation
of recent myocardial infarction (MI) (< 30 days). Overall, patients were treated with
approximately 8,500 DES and angiographic success was high (>99%) despite rela-
tively high complexity in the majority of lesions (67% type B2/C). Up to 12 years
(median 4.9 years) FU, cumulative incidence of ST was 2.4%, given that 95.1% of
patients were ST-free at 10 years (Kaplan-Meier survival curve). Of the 113 ST re-
ported, 13% occured up to 30 days, 55% were deﬁnite ST (ARC), and >60% occured
12 months. Independent predictors of ST are shown in the Table.13–17, 2014 j TCT Abstracts/Stents - Drug-Eluting: Stent Thrombosis
